LONG TERM USE OF DAB(389)IL 2 THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS

类风湿性关节炎患者长期使用 DAB(389)IL 2 疗法

• 批准号: 6118957
• 负责人: K LEA SEWELL
• 金额: $ 2.98万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118957
• 关键词: clinical research; drug screening /evaluation; human subject; human therapy evaluation; immunotherapy; interleukin 2; longitudinal human study; rheumatoid arthritis

This open-label compassionate use study of DAB(389)IL-2 in patients with rheumatoid arthritis who have previously received infusion courses of this agent under compassionate use and who experienced clinical improvement with acceptable toxicity.

这项DAB(389)IL-2的开放标签同情性用法研究在类风湿性关节炎患者中进行，这些患者以前曾在同情性使用下接受过该药的输注疗程，并经历了临床改善，毒性可接受。